Last month HLS delivered a solid report including a 190% increase in net profit and for the 1st 6-months of 2021 over $950m of revenue, up 16% year on year. Obviously the companies enjoyed a COVID generated surge in revenue through its pathology department but we believe some of this will be maintained as the world moves to a new norm post the pandemic. This is a business we believe is stronger following the sale of its medical and dental centres and although the takeover potential has reduced as the stock rallies we like its outlook moving forward.
MM likes HLS moving through 2021.
Add To Hit List
